Phase 3 Readout
DFTX: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a
November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 1, 2026
- Company
- Definium Therapeutics Inc. (DFTX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a
- Indication
- Generalized Anxiety Disorder